|This Slide: #82 of 100|
Slide #82. Alnylam Pharmaceuticals, Inc. — Merck's Sirna Therapeutics Subsidiary
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Merck's Sirna Therapeutics Subsidiary
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics" or "Sirna") has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant to which Alnylam agreed to purchase from Merck all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. In consideration for the Sirna common stock, Alnylam paid Merck $25.0 million in cash. In addition, Alnylam agreed to issue to Merck 2,520,044 shares of Alnylam common stock, having a value of $150.0 million as calculated under the terms of the stock purchase agreement on the date of execution, and representing an approximately 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares upon the completion of certain technology transfer activities pursuant to the terms of the stock purchase agreement.
Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi). RNAi is a biological pathway within cells for sequence-specific silencing and regulation of gene expression. Co. has two RNAi-based medicines, ONPATTRO® (patisiran) and GIVLAARI® (givosiran). ONPATTRO is approved by the United States Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and has also been approved in the European Union, Japan, Canada and Switzerland. GIVLAARI is approved by FDA for the treatment of adults with acute hepatic porphyria.
ALNY SEC Filing Email Alerts Service
Open the ALNY Page at The Online Investor »
Buy (3.25 out of 4)